Characteristics of Lung Cancers Harboring NRAS Mutations
暂无分享,去创建一个
M. Ladanyi | C. Rudin | M. Kris | W. Pao | H. Sasaki | L. Sequist | J. Engelman | M. Arcila | D. Dias-Santagata | Gregory Riely | P. Bunn | W. Franklin | M. Sos | D. Camidge | C. Lovly | Xi Chen | C. Vnencak-Jones | S. Dubinett | E. Garon | T. Morán | K. Ohashi | L. Berry | Yumei Pan
[1] Robin Talbot,et al. Analysis and interpretation of data , 2014 .
[2] F. McCormick,et al. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. , 2013, Cancer discovery.
[3] Chandrani Chattopadhyay,et al. Association of activated c‐Met with NRAS‐mutated human melanomas , 2012, International journal of cancer.
[4] Carla Mattos,et al. A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.
[5] Yasushi Totoki,et al. KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.
[6] Yuki Togashi,et al. RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.
[7] Doron Lipson,et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.
[8] D. Bar-Sagi,et al. Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis , 2012, Nature Communications.
[9] William Pao,et al. Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[11] S. Digumarthy,et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] M. Ladanyi,et al. Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling , 2011, Molecular Cancer Therapeutics.
[13] A. Iafrate,et al. Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers , 2011, PloS one.
[14] D. Bar-Sagi,et al. RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.
[15] Jeffrey W. Clark,et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.
[16] Antonio Marchetti,et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Ladanyi,et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] N. Girard,et al. New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.
[19] A. Iafrate,et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. , 2011, The Journal of molecular diagnostics : JMD.
[20] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[21] A. Gemma,et al. F1000 highlights , 2010 .
[22] David N Louis,et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.
[23] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[24] William Pao,et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer , 2009, Proceedings of the National Academy of Sciences.
[25] William Pao,et al. High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507) , 2009, PloS one.
[26] Laura Tolosi,et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.
[27] William Pao,et al. Genetic predictors of MEK dependence in non-small cell lung cancer. , 2008, Cancer research.
[28] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[29] W. Lam,et al. PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.
[30] Li Ding,et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.
[31] M. Ladanyi,et al. Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.
[32] A. Sweet-Cordero,et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.
[33] J. Settleman,et al. Activated Kras, but Not Hras or Nras, May Initiate Tumors of Endodermal Origin via Stem Cell Expansion , 2008, Molecular and Cellular Biology.
[34] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[35] S. Gabriel,et al. High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.
[36] J. Minna,et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.
[37] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[38] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[39] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[40] J. Hancock,et al. Ras proteins: different signals from different locations , 2003, Nature Reviews Molecular Cell Biology.
[41] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[42] D. Sidransky,et al. Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.
[43] M. Malumbres,et al. Targeted Genomic Disruption of H-ras and N-ras, Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and Development , 2001, Molecular and Cellular Biology.
[44] P. Hainaut,et al. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.
[45] S. Hecht,et al. Tobacco smoke carcinogens and lung cancer. , 1999, Journal of the National Cancer Institute.
[46] R. Kucherlapati,et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. , 1997, Genes & development.
[47] T. Koh,et al. N-ras mutation in 7,12-dimethylbenz[a]anthracene (DMBA)-induced erythroleukemia in Long-Evans rats. , 1995, Cancer letters.
[48] M. Wigler,et al. Three human transforming genes are related to the viral ras oncogenes. , 1983, Proceedings of the National Academy of Sciences of the United States of America.